Execution at Scale: Can MTAR Sustain the 130% Growth Arc?
With ₹2,300 Cr in order backlog and Q1 FY27 revenue up 130% YoY, MTAR enters Q2 in full flow. The print will test whether the company can convert large NPCIL and international orders on track—and whether margins hold amid execution ramp.
The Setup: Unprecedented Order Backlog, Execution Under Way
MTAR Technologies has shifted from a cyclical orders-led story into a multi-year execution visibility play. Q1 FY27 delivered a headline—revenue surged 130% YoY to ₹360.7 Cr—but the deeper signal is the order book: now estimated at ~4.6x FY26 revenue, providing multi-year earnings visibility that the Street has not seen before. Two headline orders frame this quarter: the NPCIL coolant channel assembly order (₹126.74 Cr, Aug 2026) and the prior order value amendment of ₹819.94 Cr (Jul 2026). The real Q2 story is whether the company's manufacturing and supply-chain can sustain the Q1 run-rate while maintaining profitability under the ramp.
~₹350–380 Cr
On Q1 FY27 trajectory (130% YoY); orders queued for H1 FY27 execution
~4.6x revenue
Sufficient for multi-year guidance; de-risks near-term growth
EBITDA ~18–20%
Q1 margins vs. Q2 under higher execution; pricing-in of input cost inflation
On-plan execution
NPCIL + international orders; delivery schedules vs. actual dispatch
What a Strong vs. Weak Print Looks Like
Strong print: Revenue ₹365–385 Cr (sustaining the 130% YoY run-rate or higher), EBITDA margin ≥19%, order inflow > executed value, management reaffirms or raises full-year guidance. Colour on NPCIL delivery timelines, aerospace/nuclear sector traction, and cash conversion efficiency. Weak print: Revenue <₹340 Cr (pullback from Q1 trajectory), EBITDA margin <17% (suggesting input cost or execution inefficiency), guidance scaled back, or supply-chain/order execution delays flagged. Any commentary on order book delays or pricing pressure from government buyers.
On Track to Guidance?
The company raised FY27 guidance earlier in the year and has not issued formal full-year expectations in Q1 earnings, but the order book math suggests the company is tracking well: ₹2,300 Cr+ backlog at 4.6x FY26 revenue implies multi-year revenue runways. The Street consensus points to strong mid-to-high 20s growth for FY27 (25–35% range), consistent with the Q1 print. A Q2 revenue print in the ₹350–380 Cr band would keep the company on pace for FY27 delivery; a miss would raise questions about execution capacity and timeline slippage.
Since Last Quarter: Filings & Corporate Action
Aug 26, 2026
NPCIL order: ₹126.74 Cr for coolant channel assemblies (refurbishment)
Near-term order visibility; nuclear sector momentum
Jul 30, 2026
Prior large order value increased by ₹819.94 Cr (USD 238.76M → revised upwards)
Upsizing signal; confidence in delivery; no change in execution timeline disclosed
Oct 16 & Sep 19, 2026
Promoter Mrs. Kavitha Reddy pledges 32,000 shares (Sep 17); Promoter Saranya Loka Reddy pledges/releases 1,05,000 shares (Aug 28)
Routine pledge activity for working capital; watch if repledges accelerate
Sep 9 & 8, 2026
Promoters K Shalini and Leelavathi Parvatha Reddy sell 18,000 + 20,000 shares on open market (early Sep)
Minor open-market sales; routine rebalancing; no material strategic signal
Oct 27, 2026
Motilal Oswal Funds acquire 50,264 shares (0.16% stake)
Institutional accumulation; positive sentiment
Oct 6, 2026
CRISIL assigns ESG Rating 'CRISIL ESG 63' (Strong category)
ESG credential; long-term governance quality signal
Sep 28, 2026
27th AGM held; FY26 Annual Report and BRSR filed
Routine governance; no material AGM outcomes flagged in filings
Summary: Operationally, two large order updates (NPCIL + prior order amendment) validate the backlog strength. Promoter pledging is routine liquidity-driven, not distress; the sales by K Shalini and Leelavathi Parvatha Reddy are minor (sub-0.1% each) and do not signal a strategic exit. FII ownership surged 748 bps QoQ to 24.79% (as of Q1 FY27), the sharpest gain in a year—a clear read of institutional accumulation confidence. ESG recognition is a long-term positive for governance quality.
1 · Revenue Run-Rate & Order Execution
Can MTAR sustain the 130% YoY growth from Q1 (₹360.7 Cr) into Q2? A print in the ₹350–380 Cr band keeps the narrative intact. Anything below ₹330 Cr would suggest execution delays or pricing headwinds. Management commentary on order dispatch timelines (NPCIL, international) will be critical—any slippage into H2 or beyond would reset full-year guidance.
2 · Margin Trajectory Under Execution
Q1 FY27 EBITDA margins are unknown (no P&L disclosed in the preview dataset), but the Street is modeling 18–21% for the full year. Q2 execution ramp could either protect or compress margins depending on input-cost pass-through and manufacturing efficiency. Watch for management guidance on pricing power and cost inflation headwinds.
3 · FY27 Guidance Confirmation & Cash Conversion
No formal FY27 full-year revenue guidance has been disclosed (as of this preview). The board meeting on Oct 29 is the inflection point: does management reaffirm the implied 25–35% FY27 growth trajectory, or temper it? Also critical: working capital swing and cash flow from operations—at this execution scale, delays in receivables or inventory buildup could pressure Q2 cash generation despite strong revenue.
MTAR Technologies enters Q2 FY27 in unprecedented momentum: Q1 revenue exploded 130% YoY, the order book sits at 4.6x annual revenue, and institutional money (FII +748 bps QoQ) is flowing in. The stock, down 23% from its ATH, has reset on valuation concerns—the Street consensus target of ₹9,223 (32% upside) bakes in sustained execution. The thesis hinges on three proving grounds: (1) Can the company sustain high-20s to 30%+ growth through FY27 while keeping margins above 18%? (2) Will NPCIL and international order timelines hold, or will slippage spill into H2 or beyond? (3) Can cash conversion keep pace with revenue, or will working capital become a drag?
If Q2 delivers revenue in the ₹350–380 Cr band with EBITDA margins ≥18%, and management reaffirms or raises FY27 guidance, the stock has room to re-rate toward ₹8,000+. But a revenue miss below ₹330 Cr, margin compression, or order timeline slippage would reset expectations sharply—consensus targets assume near-flawless execution in a complex defence/nuclear supply chain. Watch the commentary on order visibility, execution capacity, and cash flow dynamics as closely as the headline numbers.
MTAR Q2 FY27: standalone profit surges, OPM expands to 24.4%, revenue doubles YoY
PAT +1309.5% YoY · revenue +200% · margins expanding
₹406.77 Cr
+200% YoY
₹59.83 Cr
+1309.5% YoY
14.41%
+11.4pp YoY
₹19.45
MTAR Technologies reported standalone Q2 FY27 (quarter ended Sep 30, 2026) revenue from operations of ₹406.8 Cr, up ~200% YoY and 12.8% QoQ, with PAT of ₹59.8 Cr versus ₹4.2 Cr in the year-ago quarter and ₹50.2 Cr in Q1 FY27 (+19.1% QoQ). No consensus estimates specific to this quarter could be located — the print lands same-day — so vs-street is unknown; the scale of the YoY jump should be read against an unusually weak Q2 FY26 base rather than treated as a like-for-like acceleration.
Q2 FY-2027 vs prior quarters
EBITDA margin (OPM) expanded to 24.4% from 12.5% a year ago and 23.6% last quarter, sitting at the top of management's own FY27 guidance band of 24%±100bps. The expansion is operating leverage: cost of materials consumed fell to 56.1% of revenue from 60.3% YoY, and employee costs fell to 12.2% of revenue from 24.6% YoY as revenue scaled roughly 3x faster than the underlying cost base. Net margin followed, expanding to 14.4% from 3.0% YoY. PBT (₹80.3 Cr) less tax (₹20.4 Cr) reconciles exactly to reported PAT, and there were no exceptional items in either the current or year-ago quarter, so both YoY and QoQ growth sit on a clean, comparable base with nothing to adjust out.
The stock went into the print at ₹7,166.35, up 1.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters.
What the summary numbers don't show
EPS (basic) ₹19.45 for the quarter vs ₹16.33 QoQ and ₹1.38 YoY
FY27: 80% revenue growth ±5%, EBITDA margin 24% ±100 bps, order book target ₹5,000 Cr (achieved by Q1 end at ₹5,143 Cr). Management added ₹800 Cr orders today, now ₹5,943 Cr. Reaffirmed confident to beat 80% and 24% targets.
— This quarter: beat
Management's FY27 guidance (set on the Aug 2026 call) calls for 80% full-year revenue growth and 24%±100bps EBITDA margin; H1 FY27 revenue of ₹767.5 Cr is already up 162.7% YoY over H1 FY26's ₹292.2 Cr, well ahead of pace on the revenue target, while the 24.4% Q2 OPM print sits at the guided margin ceiling — both reaffirm the confident tone from that call rather than contradict it. The company's last disclosed order book, also from the Aug 2026 call, stood at ₹5,943 Cr after adding ₹800 Cr that day, already above the ₹5,000 Cr FY27 target; this filing carries no updated order-book number. Separately, after the quarter closed, the NCLT approved (Oct 28, 2026) the merger of Gee Pee Aerospace and Magnatar Aero Systems into the company retrospective to April 1, 2025; MTAR accounted for it via pooling-of-interests with prior periods restated (impact stated as not material), and the company now reports standalone-only. No management press release accompanying this result was available to quote; the board-meeting-outcome letter covers only the approval mechanics and the merger order.
W1
Whether OPM holds near the 24%±100bps guided band in Q3 FY27 as the YoY comparison base normalizes
W2
Updated order-book figure at the Q3 FY27 concall — last disclosed was ₹5,943 Cr (Aug 2026 call), already above the ₹5,000 Cr FY27 target
W3
Full-year revenue growth tracking against the 80% FY27 guidance — H1 running at +162.7% YoY; watch if H2 capacity ramp (₹112.9 Cr capital WIP) sustains that pace